Tumor immune checkpoint therapy and the drug delivery strategies
10.16438/j.0513-4870.2021-1150
- VernacularTitle:肿瘤免疫检查点治疗及其药物递送策略
- Author:
Pei-shan LI
;
Yi-xuan LIU
;
Ying XIE
;
Yu-xin REN
;
Ming CHEN
;
Gui-ling WANG
;
Wan-liang LÜ
- Publication Type:Research Article
- Keywords:
neoplasm;
immune checkpoint inhibitor;
immune tolerance;
programmed cell death protein 1/programmed cell death ligand 1;
rug delivery system
- From:
Acta Pharmaceutica Sinica
2022;57(1):13-24
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immune checkpoint therapy is a clinical treatment strategy developed based on the new principle of the inhibition of negative immune regulation. In this article, the tumor immune checkpoint therapy and the drug delivery strategies were reviewed, mainly including immunity and tumor therapy, tumor immune checkpoint therapy and its mechanism of action, clinical application of tumor immune checkpoint therapy and therapeutic drugs, immune resistance of programmed cell death protein 1 (PD1)/programmed cell death ligand 1 (PDL1) treatment and countermeasures, drug delivery strategies for tumor immune checkpoint therapeutic agents, etc. As a revolutionary new immunotherapy strategy, tumor immune checkpoint therapy has shown obvious superior therapeutic efficacy in a variety types of tumor. However, tumor immune checkpoint therapy is also faced with a big challenge, namely, immunotherapy resistance. With the discovery of new mechanism, the continuous development of new therapeutic drugs and delivery strategies, tumor immune checkpoint therapy is expected to further improve the clinical efficacy of tumor.
